STEQEYMA 90 MG/ML SYRINGE
FDA nonproprietary name: ustekinumab-stba
For 1 mL
Pharmacies pay
$3,931.99 filed
1 × $3,931.985 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part B pays
$260.10 derived
1 × $260.10 per ML, Part B limit
Medicare's price is not your price.
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
The spread
0.07× estimated
These two figures may not measure the same thing
At 0.07×, the Medicare figure is 0.2 times what pharmacies pay or less. A gap that large means the two figures may not describe the same unit or product, or the price may have changed between their dates; check what each one covers before relying on the multiple.
Only one labeler, Celltrion USA, INC. (written “Celltrion USA, INC.” and “Celltrion USA, Inc.” on the crosswalk), is listed for HCPCS Q5099 on the CMS crosswalk, but the payment limit file’s Notes for the code say “"lesser of" methodology applied; 8% of reference add-on applied”, so the limit is not worked out from that company’s own sales price alone.
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
Cost-plus estimate
$4,526.79 estimated
$3,931.99 + $589.80 (15%) + $5.00 fee per fill = $4,526.79
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
STEQEYMA 90 MG/ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ustekinumab-stba, under the trade name “STEQEYMA”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is CELLTRION USA, Inc.
FDA lists it under 2 Established Pharmacologic Classes: Interleukin-12 Antagonist and Interleukin-23 Antagonist.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 72606-0028-01.
NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $3,931.99 for 1 mL (1 × $3,931.985 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
The NDC
- 72606-0028-01 · CELLTRION USA, Inc. · $3,931.985 per ML · eff. 2026-09-23 filed
Compared with its class
Its NADAC price is $3,931.985 per ML filed.
Of the 4 other products in FDA’s Interleukin-12 Antagonist class priced per ML, 2 have a higher middle NADAC price and 2 a lower one. The one in the middle is YESINTEK 90 MG/ML SYRINGE, at $2,902.87833 per ML filed (eff. 2026-09-23).
Of the 10 other products in FDA’s Interleukin-23 Antagonist class priced per ML, 8 have a higher middle NADAC price and 2 a lower one. The one in the middle is TREMFYA 100 MG/ML SYRINGE, at $14,728.90533 per ML filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part B’s payment limit for HCPCS Q5099, for 2026-10-01 to 2026-12-31, comes to $260.10 for 1 mL, or $260.10 per ML once converted to NADAC’s unit for this product.
Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.
The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.578 per 1 MG.
Medicare's price is not your price.
What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
- If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why does this page start at 1 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 1 mL in one package for this product’s NDC (“1 SYRINGE in 1 CARTON (72606-028-01) / 1 mL in 1 SYRINGE”), so the card starts at one package: 1 ML. Change it to match your prescription.